Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Biologics, with their precision targeting, expand treatment options for a multitude of diseases - from cancer to autoimmune disorders. In 2023 alone, 10 antibody therapeutics received their first ...

While humanized animal models are relatively new to drug development compared to their non-humanized counterparts, they are critical tools in the landscape of biologic drug development. Their success ...

Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to ...

The two drug candidates that AbCellera Biologics is developing have reached Phase 1 of clinical trials, but it will require years to be commercialized if they are developed successfully. None of the ...

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

In Darwinian terms, survival isn’t a matter of being the biggest, the fastest, or the strongest of the species, but instead ...